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Computer-aided design of human sialyltransferase inhibitors of hST8Sia III 
Abstract 
Sialyltransferase (ST) upregulation and the resultant hypersialylation of tumour cell surfaces is an 
established hallmark of many cancers including lung, breast, ovarian, pancreatic and prostate cancer. The 
role of ST enzymes in tumour cell growth and metastasis, as well as links to multi-drug resistance, has 
seen ST inhibition emerge as a target for potential antimetastatic cancer treatments. The most potent of 
these reported inhibitors are transition-state analogues. Although there are several examples of these in 
the literature, many have suspected poor pharmacokinetic properties and are not readily synthetically 
accessible. A proposed solution to these problems is the use of a neutral carbamate or 1,2,3-triazole 
linker instead of the more commonly used phosphodiester linker, and replacing the traditionally utilised 
cytidine nucleotide with uridine. Another issue in this area is the paucity of structural information of 
human ST enzymes. However, in late 2015 the structure of human ST8Sia III was reported (only the 
second human ST described so far), creating the opportunity for structure-based design of selective ST8 
inhibitors for the first time. Herein, molecular docking and molecular dynamics simulations with the newly 
published crystal structure of hST8Sia III were performed for the first time with selected ST transition 
state analogues. Simulations showed that these compounds could participate in many of the key 
interactions common with the natural donor and acceptor substrates, and reveals some key insights into 
the synthesis of potentially selective ST inhibitors. 
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Abstract: Sialyltransferase (ST) upregulation and the resultant hypersialylation of tumour cell 
surfaces is an established hallmark of many cancers including lung, breast, ovarian, pancreatic 
and prostate cancer. The role of ST enzymes in tumour cell growth and metastasis, as well as 
links to multi-drug resistance, has seen ST inhibition emerge as a target for potential 
antimetastatic cancer treatments. The most potent of these reported inhibitors are transition-
state analogues. Although there are several examples of these in the literature, many have 
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suspected poor pharmacokinetic properties and are not readily synthetically accessible. A 
proposed solution to these problems is the use of a neutral carbamate or 1,2,3-triazole linker 
instead of the more commonly used phosphodiester linker, and replacing the traditionally 
utilised cytidine nucleotide with uridine. Another issue in this area is the paucity of structural 
information of human ST enzymes. However, in late 2015 the structure of human ST8Sia III 
was reported (only the second human ST described so far), creating the opportunity for 
structure-based design of selective ST8 inhibitors for the first time. Herein, molecular docking 
and molecular dynamics simulations with the newly published crystal structure of hST8Sia III 
were performed for the first time with selected ST transition state analogues. Simulations 
showed that these compounds could participate in many of the key interactions common with 
the natural donor and acceptor substrates, and reveals some key insights into the synthesis of 
potentially selective ST inhibitors. 
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Hyperglycosylation of tumour cells, in particular hypersialylation due to overexpression of 
sialyltransferases (STs) is a well-established hallmark of cancer, which makes the development 
of selective inhibitors a vital area of inquiry in cancer treatment.[1-3] STs are enzymes of the 
glycosyltransferase family that catalyse the formation of an α-glycosidic bond between the C2 
atom of a sialic acid (N-acetylneuraminic acid, or Neu5Ac) and a hydroxyl group of a glycan 
acceptor.[4-5] In humans all, STs utilise the common donor cytidine monophosphate Neu5Ac 
(CMP-Neu5Ac). There are 20 different human sialyltransferase enzymes which catalyse the 
biosynthesis of cell surface glycoconjugates.[6-8] These subtypes are each expressed in different 
cell types, potentially allowing for specific targeting of the enzymes, which are overexpressed 
in many forms of cancer such as colorectal,[9-10] breast,[11] and pancreatic cancer.[12] Selective 
targeting of specific ST subtypes has been shown to be crucial in order to avoid off-target 
effects such as liver and kidney dysfunction (in mice), which has been observed for global 
inhibitors.[13] 
STs are named according to the position of the glycosidic bond that they catalyse, and the 
glycan acceptor to which the sialic acid is bound. In humans four families of STs exist, which 
catalyse the formation of an α-glycosidic linkage between the 2′ position of the sialic acid donor 
and the 3′, 6′, and 8′ hydroxyl group of the glycan acceptor.[5] These are classified as ST3, ST6, 
and ST8 respectively, followed by the sugar molecule to which they form the linkage (e.g. Gal, 
GalNAc, Sia). The ST8Sia subfamily (of which there are six members) catalyse an α-2,8 
linkage between two sialic acids, while having different specificities for the length of the sialic 
acid acceptor. Within this subfamily, ST8Sia III is the only member which shows a specificity 
for oligosialic acids.[14] 
ST8Sia III is a membrane-bound enzyme fixed to the Golgi apparatus, with the catalytic 
domain located in the lumen (Figure 1).[4] In the literature, ST structures have been resolved 
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for nine species of bacteria[4,15-22] and only four different mammalian structures.[7,14,23-24] The 
porcine ST3Gal I (pST3Gal I)[23] was resolved in 2009, both rat[24] and human[7] ST6Gal I 
(rST6Gal I and hST6Gal I respectively) in 2013, and most recently in 2015, the structure of 
human ST8Sia III (hST8Sia III)[14] has been determined, co-crystallised with various 
substrates, such as 5'-O-[(R)-[(S)-[3-(acetylamino)phenyl](phosphono)methoxy](hydroxy) 
phosphoryl] cytidine (55T).[25] These new structures allow for comparisons to be made between 
binding sites, to investigate potential avenues for selective inhibitor design. 
Previous studies into ST inhibitors have identified transition-state analogues as the most potent 
reported to date.[2,26-28] These compounds mimic the planar oxocarbenium-like transition-state 
of the ST mechanism, using the sialic acid donor CMP-Neu5Ac (1) as a starting point (Figure 
2). Some of the earliest compounds (such as 2, Ki = 350 nM; α-2,6-ST) added a planar bond to 
the sialic acid mimic, and replaced the carboxylate group with a phosphonate, giving markedly 
improved activity.[29] Replacing the sialic acid mimic with a simpler meta-phenoxy aromatic 
system, resulted in a further increase in potency giving one of the most potent human ST 
inhibitors to date, compound 3 (Ki = 19 nM; hST6Gal I ).[30-31] However, there are perceived 
pharmacokinetic issues with this compound, as it is believed that the phosphodiester linkage 
may be susceptible to cleavage by phosphatases in vivo (and potentially cleavage by the STs 
themselves, as the CMP leaving group is still present), rendering the compound inactive.[32] To 
address this issue, it has been proposed that replacing the charged phosphodiester linkage with 
a neutral carbamate (4), or 1,2,3-triazole (6), group could improve drug-likeness of the 
inhibitors.[33-34] Another potential alteration to the lead compound 3 is the exchange of the 
cytidine moiety with a uridine (5 and 7), in order to aid synthetic accessibility and to probe 
potential selectivity between ST subtypes. 
The aim of this study is to develop an understanding of the specificities of ST8Sia III by 
computational analysis of ligand-protein interactions, using compounds 4-7 as a starting point. 
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With comparison with previous work on ST6Gal I,[33,35] this will inform the rational design of 
potent and selective ST inhibitors with favourable pharmacokinetic properties. 
METHODS 
General Docking Procedure: Potential inhibitors (4-33) were docked into the binding site of 
one monomer of the hST8Sia III crystal structure (PDB ID:5CXY)[25] with AutoDock Vina 
(AD-Vina) version 1.1.2.[36] Receptor structures were prepared for docking using 
AutoDockTools (ADT) version 4.2.6.[37] The three-dimensional structure of the inhibitors were 
prepared utilising ChemDraw 15.0 and Avogadro v1.1.1.[38] ADT was used to assign both rigid 
and rotatable bonds and to remove non-polar hydrogens. Docking was performed for a box of 
30 Å × 30 Å × 30 Å centred at the active site. The dimension was chosen to ensure it was large 
enough to cover all key active site residues identified in hST8Sia III by Volkers et al.[14] and 
to accommodate the largest ligand investigated herein. The docking procedure was validated 
by re-docking to replicate the crystallographically determined hST8Sia III-55T complex 
(Figure 1). The receptor is treated as rigid and no explicit waters have been included. The top 
ranked models for each compound tested based on the binding affinities calculated by AD-
Vina were evaluated based upon comparison to the position of 55T in the crystal structure of 
hST8Sia III (Figure 1)[25] with VMD v1.9.2.[39] Ranking of inhibitors according to docking 
results was further validated by docking compounds with known inhibition values from 
biological testing (unpublished data – personal communication, Gerardy-Schahn, R). Statistical 
analysis was undertaken on the calculated binding affinities for each compound to determine 
if they were statistically different from one another, using a two-tailed students t-test. Results 
were deemed significant for P < 0.05. 
Molecular Dynamics Simulations: Molecular systems for MD simulations were prepared 
using VMD v1.9.2.[39] For simulations involving a ligand, the ligand was docked into the 
crystal structure using AD Vina according to the method above (See Table 1 for a description 
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of the simulations carried out). The simulated ligands varied in the linker used; carbamate 
(CAR), 1,2,3-triazole (TRI), and phosphodiester (LEAD). The system was prepared by 
solvating the protein crystal structure in a water box, with a space of at least 9.0 Å from each 
side of the surface of the protein. The water box was also ionised with NaCl to a concentration 
of 0.15 mol/L. MD simulation was carried out with NAMD 2.11,[40] and the force fields used 
were the CHARMM PARAM36 force field for the protein,[41] and force field parameters 
specific to the ligands which were generated by Montgomery et al.[33] using cGenFF[42] and 
optimised using the GAAMP method.[43-44] The systems were simulated in periodic boundary 
conditions using the Langevin algorithm for maintaining the temperature at 298.15 K, and the 
Langevin Piston Nose-Hoover method to keep the pressure constant at 1.0 bar.[45-46] Van der 
Waals forces were treated with a cut-off distance of 12.0 Å with a smoothening function 
between 10.0 and 12.0 Å , while electrostatic interactions were calculated using the Particle 
mesh Ewald method.[47] Covalent bonds involving hydrogen had their rigidity maintained by 
the RATTLE algorithm.[48] The integration time step was set to 1.0, 2.0, and 4.0 fs for bonded, 
non-bonded, and long range electrostatic interactions respectively. Triplicated equilibrium 
simulations were undertaken for each system, for the first 10 ns with a harmonic restraint placed 
upon the Cα atoms of the protein with a decreasing force constant over the 10 ns. The force 
was halved every nanosecond of simulation, starting from 32.0 kcal/mol/Å2 until the force 
constant reached 1.0 kcal/mol/Å2, which was applied for the remainder of the first 10 ns of 
simulation. The simulations were then run for a further 90 ns without any restraints, with 
snapshots saved every picosecond (1000 steps). In total, 1.9 microseconds of simulations were 
carried out. 
RMSD and RMSF Analysis: In order to analyse the structural changes in the protein over the 
course of the simulations, root-mean-square deviation (RMSD) of protein Cα atoms and 
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ligands, and root-mean-square fluctuation (RMSF) of Cα atoms with respect to the starting 
structure were calculated for the course of each simulation, using VMD v1.9.2.[39] 
ST8Sia III-ligand Interaction Analysis: For the MD simulations performed, key interactions 
were analysed using CHARMM v.38a1,[49] according to specific criteria. Hydrogen bonds were 
defined by a maximum donor-acceptor distance of 3.0 Å, and minimum donor-hydrogen-
acceptor angle of 120°, with minimum 10% occupancy. Water-bridged hydrogen bonds were 
defined via the same variables, with a minimum of 30 % occupancy. Hydrophobic contacts 
were defined by a maximum distance between hydrophobic atom pairs of 4.0 Å, with minimum 
10% occupancy. 
RESULTS AND DISCUSSION 
Investigation of hST8Sia III crystal structure 
The crystal structure of hST8Sia III was recently published by Volkers et al.[14] in 2015. In the 
study, hST8Sia III was crystallised as an apo structure, and with three substrates; cytidine 
diphosphate (CDP), cytidine triphosphate (CTP) and the natural donor mimic CMP-3FNeu5Ac 
(along with the acceptor Sia-6S-LacNAc). It was also demonstrated that hST8Sia III adopts a 
dimeric structure in solution, which is believed to contribute to stabilisation and membrane 
tethering, rather than a change in activity.[14] This is contrary to the ST8Sia II and IV subtypes, 
which appear to be monomeric.[14] There was a flexible loop observed in hST8Sia III over the 
active site between residues Lys341-His354, which was not fully resolved in all but one crystal 
structure (hST8Sia III co-crystallised with CDP). This indicates that the loop is highly 
disordered, which is proposed to adopt a number of conformational states. There is also a 
hydrophobic patch above the donor binding site (Lys349-Ser353), which is believed to play a 
role in acceptor specificity within the ST8Sia enzyme family.[14] The His354 residue is believed 
to be a catalytic residue for ST8Sia III, and is observed interacting with the O8′ of the acceptor 
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sialic acid.[14] To date, there have been no computational studies performed on hST8Sia III for 
the purposes of inhibitor design and so herein is described the first of this type performed on 
this enzyme. A crystal structure was also released on the PDB by Volkers & coworkers in 2016 
with ST8Sia III co-crystallised with 5'-O-[(R)-[(S)-[3-(acetylamino)phenyl](phosphono) 
methoxy](hydroxy)phosphoryl]cytidine (55T), which has a comparable structure to the lead 
ST inhibitor (3, Figure 2).[25] These recent developments indicate the potential for development 
of selective inhibitors, with the availability of multiple crystal structures of these human ST 
enzymes giving the opportunity for structure-based drug design for the first time. 
Comparison between binding sites of pST3Gal I, hST6Gal I, and hST8Sia III 
To gain an insight into the potential structural features of selective hST8Sia III inhibitors, 
structural alignment of three mammalian STs (pST3Gal I, hST6Gal I, and hST8Sia III) was 
performed using BIOVIA Discovery Studio Visualizer,[50] centred around the donor molecule 
binding pocket (Figure 3). It was observed that for both pST3Gal I (85 % homology to hST3Gal 
I) and hST8Sia III, there was a hydrophobic sub-pocket adjacent to the 2′ position on the ribose 
ring of the co-crystallised ligands (shown by the colour gradient in Figure 3). Hydrophobicity 
was calculated using the method of Kyte and Doolittle, which assigns a value to each amino 
acid based on its hydrophobicity.[51] These values then contribute to the averaged surface 
hydrophobicity. There is also a sub-pocket present in the hST6Gal I structure, although it was 
smaller than in the other two subtypes, and offset from the 2′ position. This indicates that 
pST3Gal I and hST8Sia III may tolerate inhibitors with substitutions on the 2′ position, while 
hST6Gal I will not, as has been shown experimentally.[2] It appears that the sub-pocket 
mentioned is also larger for pST3Gal I than for hST8Sia III, which could lead to further 
selectivity between the two (if hST3Gal I adopts the same binding pocket structure). 
Stability and flexibility of the hST8Sia III-ligand complexes 
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The effects of ligand binding on the structural stability and flexibility of hST8Sia III over the 
course of the MD simulations were assessed. The RMSD of protein carbon alphas (Cα) for all 
simulations converged between 1.5 and 2.5 Å (Figure S1-S7), indicating that there was no 
significant change in the overall structure of the protein. The heavy atom positional RMSD of 
the ligand in the carbamate (CAR) simulations converged between 1.5 and 2.5 Å (Figures S8 
and S9), the phosphodiester (LEAD) simulations converged between 2.0 and 2.5 Å (Figures 
S10 and S11), triazole (TRI) simulations converged between 2.0 and 3.5 Å (Figures S12 and 
S13), except for one of the (S)-triazole (TRI_S) simulations, which stabilised at 1.5 Å. This 
indicates that the more flexible carbamate and phosphodiester linked compounds were better 
able to fit in the binding site of ST8Sia III and adopt a more stable conformation, as opposed 
to the more rigid triazole compound. In terms of the RMSF of the protein Cα atoms, all ligand-
protein complex simulations exhibited lower RMSF values for the flexible loop from Lys341 
to His354 than those observed for the apo simulation, which peaked at 3.5 Å (Figure 4). This 
effect is due to favourable ligand-protein interactions that serve to stabilise the loop. Of these 
simulations, the triazole complexes exhibited the smallest change in RMSF for the loop, which 
was between 1.5 and 3.5 Å (Figure S16). This may be due to the rigidity of the triazole linker, 
which necessitates additional movement by the protein to accommodate it. 
Comparison of the binding modes of carbamate- and 1,2,3-triazole-linked inhibitors with 
hST8Sia III 
Docking of potential inhibitors (4-27) of ST8Sia III and their phosphodiester equivalents (3, 
28-38) into snapshots (20 ns intervals from 0-100 ns) from the carbamate simulation (CAR_R1) 
was undertaken (results from statistical analysis in Tables S1-S17). The compounds were 
chosen based on a previous study by Montgomery et al,[33] to assess their difference in binding 
against hST6Gal I. Statistical analysis was performed to determine if the differences between 
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the calculated binding affinities were significant. The analysis gave a wide range of p-values, 
ranging from 7.16 ×10-6 to 1 across different comparison pairs. 
Across all compounds analysed, there was no significant difference between the binding 
affinities of the R and S stereoisomers of the same compounds. Although this is 
counterintuitive, this result correlates with previously observed experimental and 
computational results for other STs.[30,33] This appears to be due to the relatively larger space 
available in the binding site, while still allowing for the ligand to interact with residues that are 
key for binding. 
There was also no significant difference in the binding affinities of cytidine (3, 4, 6, 8-12, 18-
22, 28-32) and uridine (5, 7, 13-17, 23-27, 33-38) derivatives of the same compounds (Table 
2, 3 and 4). This suggests that there may be no specificity observed in hST8Sia III for cytidine-
based compounds over uridine based. This could open a door to selective inhibitor design, as 
the cytidine moiety is believed to be crucial to the activity of hST6Gal I inhibitors (although 
there is experimental evidence that hST3Gal I could also accept uridine derivatives).[2,7] The 
two derivatives also exhibited near-identical predicted binding modes (Figure 5A). This result 
suggests that uridine derivatives of ST inhibitors may be selective against ST6Gal I, and that 
they may be a viable (and more synthetically accessible) alternative than their cytidine 
equivalents.  
The phosphodiester-linked compounds tested did not show any significant differences in 
binding affinity compared to their carbamate- and 1,2,3-triazole-linked equivalents, suggesting 
that the use of carbamate and 1,2,3-triazole linkers do not have any major effect on the binding 
mode of these potential ST inhibitors. 
While not statistically significant in the majority of cases, it was noted that each 1,2,3-triazole-
linked derivative produced a greater binding affinity than its carbamate-linked equivalent (with 
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the single exception of (R)-11 exhibiting a higher average binding affinity than (R)-21, which 
was greater by 0.1 kcal/mol, a difference which was not statistically significant). This result 
indicates that the differences in binding affinities of compounds with 1,2,3-triazole- and 
carbamate-linkers are not significant and in fact comparable to one another.  
In terms of the binding modes of the potential inhibitors, it was noted that there were two main 
binding pockets towards which the sialyl mimic segment of the inhibitor was directed, with a 
third conformation being less frequent (demonstrated in Figure 5B). This indicates that there 
is a reasonable degree of flexibility in the structure of potential inhibitors in the region 
traditionally occupied by the sialyl mimic. 
Effect of 2′ substitution on inhibitor binding 
To probe the effect on binding of substitutions at the 2′ position of ST inhibitors and to what 
degree they may be accommodated by the binding pocket of hST8Sia III, docking was 
performed with uridine-based carbamate derivatives (5, 39-44, Table 5). It was found that there 
was no significant difference between the calculated binding affinities of the compounds with 
substitutions up to the size of a propoxy group and the non-substituted compound (R)-5 
(Table 5). Inhibitors with substitutions larger than this (such as a benzyl group) were not able 
to adopt a suitable binding conformation, indicating a limit to the size tolerance of the sub-
pocket. 
Analysis of binding interactions between hST8Sia III and potential inhibitors 
Analyses were performed on the protein-ligand complex MD simulations as part of this work 
to determine the consistent hydrogen bonds and hydrophobic contacts between the ligands and 
protein. These interactions were then compared to the non-bonded interactions described by 
Volkers et al.,[14] identified in the X-ray crystal structures of hST8Sia III with donor and 
acceptor analogues (Figure 6). When comparing the protein-ligand interactions observed in the 
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MD simulations, there was a greater similarity between the carbamate (CAR) and 
phosphodiester (LEAD) simulations than with the triazole (TRI) simulations. 
The carbamate (CAR) and phosphodiester (LEAD) simulations were found to more closely 
mimic the interactions observed in the hST8Sia III crystal structure complex, compared to the 
TRI simulations. This may be due to the increased rigidity of the triazole linker, meaning that 
the ligand was less able to adopt a conformation which matched the donor and acceptor 
analogues. Key similarities between the carbamate (CAR) and phosphodiester (LEAD) 
simulations are shown in Figure 7. Two residues that had consistent interactions in both the 
simulations and the crystal structure include Asn167 and Thr301. The residue Asn167 was 
observed interacting with the phosphate group of the donor analogue, while in the carbamate 
(CAR) and phosphodiester (LEAD) simulations it was involved in hydrogen bonding with the 
cytidine N6 and ribose oxygen. In the case of the R stereoisomers, Asn167 also participated in 
hydrogen bonding with the carbamate and phosphodiester linkers, which indicate that they are 
effectively mimicking the phosphate of the donor analogue. In the crystal structure, Thr301 
was observed interacting with the carboxylate group of CMP-3FNeu5Ac, where as in the MD 
simulations it was interacting with the linker (in the case of the carbamate compounds), the 
3′-hydroxyl, and in the phosphodiester (LEAD) simulations, the phosphonate group, which is 
intended to be an analogue of the carboxylate. One key difference that was observed across the 
stereoisomers of the carbamate (CAR) and phosphodiester (LEAD) simulations were that the 
linker at the R stereoisomers was interacting with the Asn190 residue, while the linker of the S 
stereoisomers was interacting with His337 via a water-bridged hydrogen bond. Both residues 
are noted to interact with the phosphonate group of CMP-3FNeu5Ac in the crystal structure. 
This expands upon previous work by Montgomery et al.[33] on hST6Gal I, and indicates that 




Other hydrogen bonding interactions which were consistent between both the R and S 
stereoisomers which were not explicitly noted by Volkers et al.[14] These include the residues 
Tyr336, Trp322, and Ser168, which all had hydrogen-bonding interactions with the cytidine 
moiety, while Gly302 had interactions with both 2′ and 3′ hydroxyl groups. These residues 
appear to be important in helping to orient the nucleotide fragment of the inhibitors in the active 
site, while also allowing the sialyl mimic of the inhibitor to adopt a more favourable 
conformation in the hydrophobic pocket of the active site. 
In terms of hydrophobic contacts observed over the course of the MD simulations for the 
carbamate (CAR) and phosphodiester (LEAD) ligands, there were five residues which had 
conserved interactions across R and S stereoisomers of both ligands (Figure 8). These residues 
include Phe321, Tyr336, His337, His354, and Leu356. It was interesting that there was only 
one conserved interaction with the aromatic region of the ligands, that being between the 
catalytic residue His354 and the aromatic sialyl mimic, when it occupies a large hydrophobic 
pocket, as observed by Volkers et al.[14] A potential explanation for this observation is that 
while occupancies for specific interactions were lower than 10 %, there is a large number of 
hydrophobic residues in that region, resulting in a wide variety of hydrophobic contacts being 
made throughout the simulations. Since His354 was observed in the crystal structure to interact 
(albeit via hydrogen bonding) with the sialyl acceptor, these results indicate that these potential 
inhibitors are effective at mimicking the planar transition-state of the ST mechanism.  
While results from the triazole (TRI) simulations were less consistent with the crystal structure 
than those for the carbamate (CAR) and phosphodiester (LEAD) simulations, the protein-
ligand interactions that were observed give an insight into inhibitor design for selective 
ST8Sia III inhibitors. Two hydrogen bonding interactions that were consistent with the 
hST8Sia III crystal structure were noted (Figure 9A), with Asn167 and Thr301 being the 
residues involved in binding to the cytidine oxygen and triazole linker, respectively. 
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Hydrophobic contacts for the triazole (TRI) simulations were consistent with the carbamate 
(CAR) and phosphodiester (LEAD) simulations for the cytidine moiety, with variations at the 
sialyl mimic (Figure 9B). The triazole (TRI) simulations exhibited more consistent 
hydrophobic interactions with the sialyl mimic, with the residues Pro246, Phe249, and Phe250 
(which interacted with each of the aromatic rings in the separate R and S simulations). The 
greater consistency in hydrophobic interactions with the sialyl mimic for the triazole (TRI) 
simulations as opposed to the carbamate (CAR) and phosphodiester (LEAD) could be due to 
the relative rigidity of the triazole linker. This would mean that the sialyl mimic is less mobile 
in the binding pocket, and more consistent interactions are observed when compared to the 
simulations with more flexible interactions.  
Implications for the design of selective ST inhibitors 
Previous work by our group has highlighted the suitability for carbamate and 1,2,3-triazole 
linkers as isosteres of the charged phosphodiester group of classical ST inhibitors, particularly 
for ST6Gal I.[33-34] The results found in this study show a similar observation for inhibitors of 
ST8Sia III, with comparable binding patterns and interactions observed (particularly for the 
carbamate-linked inhibitors). The results of this study showed no significant difference in the 
calculated binding affinity of inhibitors bearing a uridine or cytidine moiety, which provides 
support for the use of uridine as a nucleotide base for ST inhibitors, particularly for ST8Sia III. 
This could be a route for the synthesis of selective inhibitors if it is found that uridine 
derivatives have a lessened binding affinity for other ST subtypes such as ST6Gal I. Results 
from both docking and MD also indicate that there is little difference in the binding modes and 
interactions between R and S stereoisomers of the same inhibitor. 
While there was little significant difference between the predicted binding affinities of the 
triazole and carbamate derivatives of the inhibitors analysed here, there was a trend of triazole 
compounds exhibiting a slightly higher binding affinity. Conclusive characterisation of such 
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effects will require rigorous binding free energy calculations. Additionally, and perhaps most 
importantly for the development of selective inhibitors, is the observation that the binding 
pocket of ST8Sia III can accommodate substitution at the 2′ position of ST inhibitors without 
a detrimental effect to their binding affinity. This is in contrast to ST6Gal I, which does not 
accommodate such substitutions.[2] These observations should be probed further and may yield 
promising results in the realm of selectivity, at the very least against ST6Gal I. 
CONCLUSIONS: 
Computational analysis of potential inhibitor binding was performed using the crystal structure 
of hST8SiaIII for the first time. A validated docking procedure was used to assess 42 distinct 
compounds and their stereoisomers. The results suggested that there was no significant 
difference in the predicted binding affinity of inhibitors bearing either a uridine or cytidine 
nucleotide moiety. Docking results also showed that there was no significant difference 
between the binding affinity of the R and S diastereomers of the proposed inhibitors. MD 
simulations determined that the proposed carbamate- and triazole-linked transition state 
analogues bound to the hST8Sia III active site in a similar conformation to the co-crystallised 
inhibitor analogue 55T, and the donor and acceptor analogues from the published crystal 
structures, while retaining some key interactions with the protein. This work provides a 
foundation for more rigorous characterisation of binding affinities and selectivities based on 
free energy calculations, which is currently underway. Furthermore, current studies also 
provide important insights for the synthetic and biological exploration of 2′-substituted 
carbamate and 1,2,3-triazole-linked ST inhibitors, which display a potential for selectivity. 
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Table 1: Summary of MD simulations performed 
Ligand Simulation Name Equilibrium steps (ns) Free Simulation (ns) Simulations Performed 
None APO 10 90 1 
(R)-4 CAR_R 10 90 3 
(S)-4 CAR_S 10 90 3 
(R)-3 LEAD_R 10 90 3 
(S)-3 LEAD_S 10 90 3 
(R)-6 TRI_R 10 90 3 


















(R)-8 -9.5 ± 0.2 (R)-13 -9.5 ± 0.2 
(S)-8 -9.3 ± 0.1 (S)-13 -9.5 ± 0.1 
 
(R)-4 -10.5 ± 0.2 (R)-5 -10.7 ± 0.2 
(S)-4 -10.4 ± 0.3 (S)-5 -10.3 ± 0.2 
 
(R)-9 -10.0 ± 0.2 (R)-14 -10.1 ± 0.1 
(R)-9 -10.0 ± 0.2 (R)-14 -10.1 ± 0.3 
 
(R)-10 -9.9 ± 0.3 (R)-15 -10.0 ± 0.3 
(S)-10 -9.7 ± 0.1 (S)-15 -9.9 ± 0.1 
 
(R)-11 -9.5 ± 0.1 (R)-16 -9.5 ± 0.1 
(S)-11 -9.3 ± 0.1 (S)-16 -9.5 ± 0.2 
 
(R)-12 -9.4 ± 0.1 (R)-17 -9.4 ± 0.2 
(S)-12 -9.3 ± 0.2 (S)-17 -9.4 ± 0.2 
 aArithmetic mean of binding affinity ± SEM obtained from docking into six snapshots of 
the CAR_R1 simulation. 
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R Cpd Mean Binding Affinity (kcal/mol)a Cpd 
Mean Binding Affinity 
(kcal/mol)a 
 
(R)-18 -9.8 ± 0.1 (R)-23 -10.0 ± 0.1 
(S)-18 -10.1 ± 0.2 (S)-23 -9.7 ± 0.3 
 
(R)-6 -10.9 ± 0.3 (R)-7 -10.8 ± 0.2 
(S)-6 -11.0 ± 0.3 (S)-7 -11.0 ± 0.3 
 
(R)-19 -10.1 ± 0.2 (R)-24 -10.3 ± 0.2 
(S)-19 -10.5 ± 0.2 (S)-24 -10.6 ± 0.2 
 
(R)-20 -10.2 ± 0.2 (R)-25 -10.1 ± 0.2 
(S)-20 -10.6 ± 0.3 (S)-25 -10.5 ± 0.2 
 
(R)-21 -9.4 ± 0.1 (R)-26 -9.7 ± 0.1 
(S)-21 -9.9 ± 0.2 (S)-26 -10.2 ± 0.2 
 
(R)-22 -9.8 ± 0.1 (R)-27 -9.7 ± 0.1 
(S)-22 -10.0 ± 0.2 (S)-27 -10.1 ± 0.2 









R Cpd Mean Binding Affinity (kcal/mol)a Cpd 
Mean Binding Affinity 
(kcal/mol)a 
 
(R)-28 -9.3 ± 0.1 (R)-33 -9.3 ± 0.2 
(S)-28 -9.3 ± 0.2 (S)-33 -9.4 ± 0.1 
 
(R)-3 -10.2 ± 0.3 (R)-34 -10.3 ± 0.3 
(S)-3 -10.3 ± 0.2 (S)-34 -10.3 ± 0.2 
 
(R)-29 -9.7 ± 0.2 (R)-35 -10.0 ± 0.2 
(S)-29 -9.8 ± 0.3 (S)-35 -10.1 ± 0.3 
 
(R)-30 -9.8 ± 0.1 (R)-36 -9.8 ± 0.2 
(S)-30 -9.9 ± 0.1 (S)-36 -9.8 ± 0.2 
 
(R)-31 -9.2 ± 0.2 (R)-37 -9.3 ± 0.1 
(S)-31 -9.4 ± 0.2 (S)-37 -9.5 ± 0.2 
 
(R)-32 -9.2 ± 0.1 (R)-38 -9.3 ± 0.1 
(S)-32 -9.3 ± 0.1 (S)-38 -9.4 ± 0.2 








R Cpd Mean Binding Affinity (kcal/mol)a 
H (R)-5 -10.7 ± 0.2 
Me (R)-39 -10.9 ± 0.3 
Et (R)-40 -10.6 ± 0.2 
Pr (R)-41 -10.2 ± 0.2 
CF3 (R)-42 -10.3 ± 0.2 
CH2CF3 (R)-43 -10.8 ± 0.2 
C6H5 (R)-44 Not accommodated 



























Figure 1: The structure of hST8Sia III (PDB id:5CXY)[25], which was crystallised with the 
ligand 55T (blue). The soluble catalytic domain of hST8Sia III extends into the lumen of the 
Golgi apparatus via a stem region from a transmembrane domain (TMD) and a short N-terminal 
cytoplasmic domain. The flexible active-site loop (residues 341-354) is coloured in red. 
Figure 2: Development of ST transition-state analogue inhibitors, from the one of the earliest 
(2),[29] to the most potent inhibitor to date (3),[30-31]  which serves as our lead. Comparisons of 
carbamate (4 and 5), and 1,2,3-triazole (6 and 7) derivatives with the lead compound will be 
the focus of this study. 
Figure 3: Comparison between the donor binding sites of pST3Gal I (left - bound to CMP; 
PDB id: 2WNB),[23] hST6Gal I (centre - bound to CMP; PDB id: 4JS2),[7] and hST8Sia III 
(right - bound to 55T; PDB id: 5CXY),[25] with the surface showing the hydrophobicity of the 
binding pocket, calculated according to the method of Kyte and Doolittle.[51] 
Figure 4: Cα RMSFs of hST8Sia III, calculated for each MD simulation. Expanded figures are 
in supplementary information (Figures S14-S16). 
Figure 5: (A) Comparison between the predicted binding modes of the m-phenoxy cytidine 
compound (R)-4 (green) and the analogous uridine compound (R)-5 (orange). (B); Comparison 
of binding conformations of the sialyl mimic of inhibitor (R)-4, with the orange conformation 
being the most common. The green binding mode gave generally higher binding affinity, with 
lower frequency, while the pink mode was the least frequently suggested by the docking 
procedure. 
Figure 6: Significant non-bonded interactions described by Volkers et al.[14] of the donor and 
acceptor analogues CMP-3FNeu5Ac and Sia-6S-LacNAc respectively, with hST8Sia III. Some 
bonding interactions involving the protein backbone and the cytidine ring of CMP-3FNeu5Ac 
are not displayed. 
Figure 7: Significant hydrogen bonding interactions of the (A) R and (B) S stereoisomers of 
the carbamate (CAR) and phosphodiester (LED) compounds with hST8Sia III across 90 ns of 
simulation. Blue residues denote those interactions which were also observed in the crystal 
structure. The red box represents the two linkers. Full interaction data shown in Tables S18, 
S20, S22, and S24. 
Figure 8: Significant hydrophobic interactions of the (A) R and (B) S stereoisomers of the 
CAR and LED simulations with hST8Sia III across 90 ns of simulation. The red box represents 
the two linkers. Full interaction data shown in Tables S19, S21, S23, and S25. 
Figure 9: Significant non-bonded interactions of triazole (TRI) with hST8Sia III across 90ns 
of free simulation in each of the six triazole (TRI) simulations. (A) Hydrogen bond analysis 
(blue residues denote those interactions which were also observed in the crystal structure), (B) 
hydrophobic contacts (grey residues denote interactions which were consistent in simulations 
of one stereoisomer). Full interaction data is shown in Supplementary Tables S26-S29. 
 
 
 
